EWA
NBIX icon

EP Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

EP Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386K Sell
2,932
-17
-0.6% -$2.26K ﹤0.01% 1024
2025
Q4 		$418K Buy
+2,949
New +$427K ﹤0.01% 961
2025
Q2 		– Sell
-3,661
Closed -$405K – 1454
2025
Q1 		$405K Sell
3,661
-150
-4% -$19K ﹤0.01% 784
2024
Q4 		$520K Sell
3,811
-380
-9% -$47K ﹤0.01% 684
2024
Q3 		$483K Buy
+4,191
New +$575K ﹤0.01% 706

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EP Wealth Advisors's NBIX Position: Q1 2026 in Review

EP Wealth Advisors reduced its Neurocrine Biosciences (NBIX) stake by 0.58% in Q1 2026, selling an estimated $2.26K and leaving 2,932 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

EP Wealth Advisors first reported a position in NBIX in Q3 2024 and has held it in 5 quarters since. The position peaked at $520K in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • EP Wealth Advisors held 2,932 shares of Neurocrine Biosciences worth $386K as of Q1 2026.
  • EP Wealth Advisors sold 17 Neurocrine Biosciences shares in Q1 2026, an estimated $2.26K.
  • Neurocrine Biosciences made up ﹤0.01% of EP Wealth Advisors's portfolio in Q1 2026, its #1024 holding.
  • EP Wealth Advisors first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 5 quarters since.
  • EP Wealth Advisors's Neurocrine Biosciences position peaked at $520K in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on EP Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.